Click for best price
Multiple Sclerosis MS Drugs Market Size, Share 2022
Market Analysis and Insights: Global Multiple Sclerosis MS Drugs Market
The global Multiple Sclerosis MS Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Multiple Sclerosis MS Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Multiple Sclerosis MS Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Multiple Sclerosis MS Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Multiple Sclerosis MS Drugs market.
Global Multiple Sclerosis MS Drugs Scope and Market Size
Multiple Sclerosis (MS) Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis (MS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application
RRMS
SPMS
PPMS
PRMS
By Company
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Multiple Sclerosis MS Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Multiple Sclerosis MS Drugs, with price, sales, revenue, and global market share of Multiple Sclerosis MS Drugs from 2019 to 2022.
Chapter 3, the Multiple Sclerosis MS Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Multiple Sclerosis MS Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Multiple Sclerosis MS Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Multiple Sclerosis MS Drugs.
Chapter 13, 14, and 15, to describe Multiple Sclerosis MS Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Multiple Sclerosis MS Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Multiple Sclerosis (MS) Drugs Market Insights, Forecast to 2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
110 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Market by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Multiple Sclerosis (MS) Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Multiple Sclerosis (MS) Drugs Sales by Region
2.4.1 Global Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Multiple Sclerosis (MS) Drugs by Region (2023-2028)
2.5 Global Multiple Sclerosis (MS) Drugs Revenue by Region
2.5.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022)
2.5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers
3.1.1 Global Top Multiple Sclerosis (MS) Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Multiple Sclerosis (MS) Drugs in 2021
3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Multiple Sclerosis (MS) Drugs Revenue in 2021
3.3 Global Multiple Sclerosis (MS) Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Multiple Sclerosis (MS) Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type
4.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type
4.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type
4.3.1 Global Multiple Sclerosis (MS) Drugs Price by Type (2017-2022)
4.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application
5.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application
5.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application
5.3.1 Global Multiple Sclerosis (MS) Drugs Price by Application (2017-2022)
5.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Multiple Sclerosis (MS) Drugs Market Size by Type
6.1.1 North America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
6.1.2 North America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
6.2 North America Multiple Sclerosis (MS) Drugs Market Size by Application
6.2.1 North America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
6.2.2 North America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
6.3 North America Multiple Sclerosis (MS) Drugs Market Size by Country
6.3.1 North America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
6.3.2 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Type
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
7.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Application
7.2.1 Europe Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
7.2.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
7.3 Europe Multiple Sclerosis (MS) Drugs Market Size by Country
7.3.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
7.3.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Type
8.1.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Application
8.2.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Region
8.3.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Multiple Sclerosis (MS) Drugs Market Size by Type
9.1.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
9.1.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
9.2 Latin America Multiple Sclerosis (MS) Drugs Market Size by Application
9.2.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
9.2.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
9.3 Latin America Multiple Sclerosis (MS) Drugs Market Size by Country
9.3.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
9.3.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Type
10.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Application
10.2.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country
10.3.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Overview
11.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer AG Recent Developments
11.2 Bayhill Therapeutics
11.2.1 Bayhill Therapeutics Corporation Information
11.2.2 Bayhill Therapeutics Overview
11.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayhill Therapeutics Recent Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Overview
11.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biogen Idec Recent Developments
11.4 Cinnagen
11.4.1 Cinnagen Corporation Information
11.4.2 Cinnagen Overview
11.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cinnagen Recent Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Overview
11.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Daiichi Sankyo Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Corporation Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Eli Lilly Recent Developments
11.7 Fast Forward Llc
11.7.1 Fast Forward Llc Corporation Information
11.7.2 Fast Forward Llc Overview
11.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fast Forward Llc Recent Developments
11.8 Antisense Therapeutics
11.8.1 Antisense Therapeutics Corporation Information
11.8.2 Antisense Therapeutics Overview
11.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Antisense Therapeutics Recent Developments
11.9 Apitope
11.9.1 Apitope Corporation Information
11.9.2 Apitope Overview
11.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Apitope Recent Developments
11.10 Five Prime Therapeutics
11.10.1 Five Prime Therapeutics Corporation Information
11.10.2 Five Prime Therapeutics Overview
11.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Five Prime Therapeutics Recent Developments
11.11 Genmab
11.11.1 Genmab Corporation Information
11.11.2 Genmab Overview
11.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Genmab Recent Developments
11.12 Artielle Immunotherapeutics
11.12.1 Artielle Immunotherapeutics Corporation Information
11.12.2 Artielle Immunotherapeutics Overview
11.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Artielle Immunotherapeutics Recent Developments
11.13 Genzyme
11.13.1 Genzyme Corporation Information
11.13.2 Genzyme Overview
11.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Genzyme Recent Developments
11.14 Glaxosmithkline
11.14.1 Glaxosmithkline Corporation Information
11.14.2 Glaxosmithkline Overview
11.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Glaxosmithkline Recent Developments
11.15 Gw Pharmaceuticals
11.15.1 Gw Pharmaceuticals Corporation Information
11.15.2 Gw Pharmaceuticals Overview
11.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Gw Pharmaceuticals Recent Developments
11.16 Innate Immunotherapeutics
11.16.1 Innate Immunotherapeutics Corporation Information
11.16.2 Innate Immunotherapeutics Overview
11.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Innate Immunotherapeutics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
12.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
12.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
12.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
12.4.2 Multiple Sclerosis (MS) Drugs Distributors
12.5 Multiple Sclerosis (MS) Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Multiple Sclerosis (MS) Drugs Industry Trends
13.2 Multiple Sclerosis (MS) Drugs Market Drivers
13.3 Multiple Sclerosis (MS) Drugs Market Challenges
13.4 Multiple Sclerosis (MS) Drugs Market Restraints
14 Key Findings in The Global Multiple Sclerosis (MS) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Copaxone (Glatiramer Acetate, Copolymer 1)
Table 3. Major Manufacturers of Novantrone (Mitoxantrone)
Table 4. Major Manufacturers of Gilenya (Fingolimod, Fty720)
Table 5. Major Manufacturers of Aubagio (Teriflunomide)
Table 6. Major Manufacturers of Tecfidera (Dimethyl Fumarate)
Table 7. Major Manufacturers of Firategrast (Sb683699, T-0047)
Table 8. Major Manufacturers of Siponimod (Baf312)
Table 9. Major Manufacturers of Others
Table 10. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 11. Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 12. Global Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 13. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2017-2022)
Table 14. Global Multiple Sclerosis (MS) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 15. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2023-2028)
Table 16. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 17. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2017-2022)
Table 18. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 19. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2023-2028)
Table 20. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2017-2022) & (K Pcs)
Table 21. Global Multiple Sclerosis (MS) Drugs Sales Share by Manufacturers (2017-2022)
Table 22. Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2017-2022)
Table 24. Multiple Sclerosis (MS) Drugs Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 25. Global Multiple Sclerosis (MS) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2021)
Table 27. Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution and Headquarters
Table 28. Manufacturers Multiple Sclerosis (MS) Drugs Product Offered
Table 29. Date of Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 32. Global Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 33. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2017-2022)
Table 34. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2023-2028)
Table 35. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 36. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 37. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2017-2022)
Table 38. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2023-2028)
Table 39. Multiple Sclerosis (MS) Drugs Price by Type (2017-2022) & (USD/Pcs)
Table 40. Global Multiple Sclerosis (MS) Drugs Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 41. Global Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 42. Global Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 43. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2017-2022)
Table 44. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2023-2028)
Table 45. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 46. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 47. Global Multiple Sclerosis (MS) Drugs Revenue Share by Application (2017-2022)
Table 48. Global Multiple Sclerosis (MS) Drugs Revenue Share by Application (2023-2028)
Table 49. Multiple Sclerosis (MS) Drugs Price by Application (2017-2022) & (USD/Pcs)
Table 50. Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 51. North America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 52. North America Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 53. North America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 54. North America Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 55. North America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 56. North America Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 57. North America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 58. North America Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 59. North America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 60. North America Multiple Sclerosis (MS) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 61. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 62. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 63. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 64. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 65. Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 66. Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 67. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 68. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 69. Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 70. Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 71. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 72. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 73. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 74. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 75. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 76. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 77. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 78. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 79. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 80. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 81. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 82. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 83. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 84. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 85. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 86. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 87. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 88. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 89. Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 90. Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 91. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 92. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 93. Latin America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 94. Latin America Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 95. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 96. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 97. Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 98. Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 100. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 101. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 104. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 105. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 107. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 108. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 109. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 110. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 111. Bayer AG Corporation Information
Table 112. Bayer AG Description and Major Businesses
Table 113. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 114. Bayer AG Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Bayer AG Recent Developments
Table 116. Bayhill Therapeutics Corporation Information
Table 117. Bayhill Therapeutics Description and Major Businesses
Table 118. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 119. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Bayhill Therapeutics Recent Developments
Table 121. Biogen Idec Corporation Information
Table 122. Biogen Idec Description and Major Businesses
Table 123. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 124. Biogen Idec Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Biogen Idec Recent Developments
Table 126. Cinnagen Corporation Information
Table 127. Cinnagen Description and Major Businesses
Table 128. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 129. Cinnagen Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Cinnagen Recent Developments
Table 131. Daiichi Sankyo Corporation Information
Table 132. Daiichi Sankyo Description and Major Businesses
Table 133. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 134. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Daiichi Sankyo Recent Developments
Table 136. Eli Lilly Corporation Information
Table 137. Eli Lilly Description and Major Businesses
Table 138. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 139. Eli Lilly Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Eli Lilly Recent Developments
Table 141. Fast Forward Llc Corporation Information
Table 142. Fast Forward Llc Description and Major Businesses
Table 143. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 144. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Fast Forward Llc Recent Developments
Table 146. Antisense Therapeutics Corporation Information
Table 147. Antisense Therapeutics Description and Major Businesses
Table 148. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 149. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Antisense Therapeutics Recent Developments
Table 151. Apitope Corporation Information
Table 152. Apitope Description and Major Businesses
Table 153. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 154. Apitope Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Apitope Recent Developments
Table 156. Five Prime Therapeutics Corporation Information
Table 157. Five Prime Therapeutics Description and Major Businesses
Table 158. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 159. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Five Prime Therapeutics Recent Developments
Table 161. Genmab Corporation Information
Table 162. Genmab Description and Major Businesses
Table 163. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 164. Genmab Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Genmab Recent Developments
Table 166. Artielle Immunotherapeutics Corporation Information
Table 167. Artielle Immunotherapeutics Description and Major Businesses
Table 168. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 169. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Artielle Immunotherapeutics Recent Developments
Table 171. Genzyme Corporation Information
Table 172. Genzyme Description and Major Businesses
Table 173. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 174. Genzyme Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Genzyme Recent Developments
Table 176. Glaxosmithkline Corporation Information
Table 177. Glaxosmithkline Description and Major Businesses
Table 178. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 179. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. Glaxosmithkline Recent Developments
Table 181. Gw Pharmaceuticals Corporation Information
Table 182. Gw Pharmaceuticals Description and Major Businesses
Table 183. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 184. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Gw Pharmaceuticals Recent Developments
Table 186. Innate Immunotherapeutics Corporation Information
Table 187. Innate Immunotherapeutics Description and Major Businesses
Table 188. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 189. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Innate Immunotherapeutics Recent Developments
Table 191. Key Raw Materials Lists
Table 192. Raw Materials Key Suppliers Lists
Table 193. Multiple Sclerosis (MS) Drugs Distributors List
Table 194. Multiple Sclerosis (MS) Drugs Customers List
Table 195. Multiple Sclerosis (MS) Drugs Market Trends
Table 196. Multiple Sclerosis (MS) Drugs Market Drivers
Table 197. Multiple Sclerosis (MS) Drugs Market Challenges
Table 198. Multiple Sclerosis (MS) Drugs Market Restraints
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Product Picture
Figure 3. Global Multiple Sclerosis (MS) Drugs Market Share by Type in 2021 & 2028
Figure 3. Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure 4. Novantrone (Mitoxantrone) Product Picture
Figure 5. Gilenya (Fingolimod, Fty720) Product Picture
Figure 6. Aubagio (Teriflunomide) Product Picture
Figure 7. Tecfidera (Dimethyl Fumarate) Product Picture
Figure 8. Firategrast (Sb683699, T-0047) Product Picture
Figure 9. Siponimod (Baf312) Product Picture
Figure 10. Others Product Picture
Figure 11. Global Multiple Sclerosis (MS) Drugs Market Share by Application in 2021 & 2028
Figure 12. RRMS
Figure 13. SPMS
Figure 14. PPMS
Figure 15. PRMS
Figure 16. Multiple Sclerosis (MS) Drugs Report Years Considered
Figure 17. Global Multiple Sclerosis (MS) Drugs Sales 2017-2028 (K Pcs)
Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 19. Global Multiple Sclerosis (MS) Drugs Revenue 2017-2028 (US$ Million)
Figure 20. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 21. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2017-2022)
Figure 22. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2023-2028)
Figure 23. North America Multiple Sclerosis (MS) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 24. North America Multiple Sclerosis (MS) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Europe Multiple Sclerosis (MS) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 26. Europe Multiple Sclerosis (MS) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 28. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 29. Latin America Multiple Sclerosis (MS) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 30. Latin America Multiple Sclerosis (MS) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 31. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales YoY (2017-2028) & (K Pcs)
Figure 32. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 33. The Multiple Sclerosis (MS) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 34. The Top 5 and 10 Largest Manufacturers of Multiple Sclerosis (MS) Drugs in the World: Market Share by Multiple Sclerosis (MS) Drugs Revenue in 2021
Figure 35. Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 36. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 37. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 38. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 39. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 40. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 41. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 42. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 43. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 44. North America Multiple Sclerosis (MS) Drugs Sales Share by Country (2017-2028)
Figure 45. North America Multiple Sclerosis (MS) Drugs Revenue Share by Country (2017-2028)
Figure 46. U.S. Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. Canada Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 49. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 50. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 51. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 52. Europe Multiple Sclerosis (MS) Drugs Sales Share by Country (2017-2028)
Figure 53. Europe Multiple Sclerosis (MS) Drugs Revenue Share by Country (2017-2028)
Figure 54. Germany Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 55. France Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 56. U.K. Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 57. Italy Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Russia Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 59. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 60. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 61. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 62. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 63. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Share by Region (2017-2028)
Figure 64. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Share by Region (2017-2028)
Figure 65. China Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Japan Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. South Korea Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. India Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 69. Australia Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 70. Taiwan Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 71. Indonesia Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 72. Thailand Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 73. Malaysia Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 74. Philippines Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 75. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 76. Latin America Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 77. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 78. Latin America Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 79. Latin America Multiple Sclerosis (MS) Drugs Sales Share by Country (2017-2028)
Figure 80. Latin America Multiple Sclerosis (MS) Drugs Revenue Share by Country (2017-2028)
Figure 81. Mexico Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 82. Brazil Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 83. Argentina Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 84. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
Figure 85. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
Figure 86. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
Figure 87. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
Figure 88. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Share by Country (2017-2028)
Figure 89. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Share by Country (2017-2028)
Figure 90. Turkey Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 91. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 92. U.A.E Multiple Sclerosis (MS) Drugs Revenue (2017-2028) & (US$ Million)
Figure 93. Multiple Sclerosis (MS) Drugs Value Chain
Figure 94. Multiple Sclerosis (MS) Drugs Production Process
Figure 95. Channels of Distribution
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed
